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A B S T R A C T
A select blend of herbal extracts, Zyflamend, inhibits tumour growth via multiple mecha-
nisms that arise through synergistic interactions between individual components.The objective
in this study was to determine if the antiproliferative effects are mediated, in part, through
the activation of AMPK signalling and inhibition of its downstream targets, lipogenesis and
mTORC1 complex. By increasing the phosphorylation of AMPK in CWR22Rv1 and PC3 pros-
tate cancer cell lines, Zyflamend decreased de novo lipid biosynthesis by decreasing the activity
of acetyl-CoA carboxylase and the expressions of fatty acid synthase and SREBP-1c, with a
concomitant up regulation of fatty acid oxidation. In addition, via AMPK, Zyflamend inhib-
ited the activity of mTORC1 complex by directly phosphorylating raptor.Treatment with AICAR
(activator of AMPK), siRNA knockdown, pharmacological inhibition, and overexpression of
AMPK were used to confirm the up regulation of AMPK by Zyflamend.These results suggest
that Zyflamend inhibited tumour cell proliferation via up regulation of AMPK signalling.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Herbs and spices have been used to enhance flavouring, colour,
aroma and stability of food, and more recently for their ben-
eficial effects in terms of their antioxidant and anti-
inflammatory properties (Srinivasan, 2014; Viuda-Martos,
Ruiz-Navajas, Fernandez-Lopez, & Perez-Alvarez, 2011). In ad-
dition to their functional properties, natural products contain
a compendium of biologically active compounds that can
promote health and well-being and potentially reduce the risk
of disease.
Zyflamend® (New Chapter, Brattleboro,VT, USA) is a blend
of 10 herbal extracts (ginger, rosemary, turmeric, Chinese
goldthread, holy basil, hu zhang, barberry, oregano, green tea
and baikal skullcap) formulated based on their antioxidant and
potentially anti-inflammatory properties. To date, there have
been 14 research articles investigating the anti-cancer effects
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of this blend, covering in vitro, preclinical and clinical studies
involving the prostate, bone, skin, kidney, breast and pan-
creas (Bemis, Capodice, Anastasiadis, Katz, & Buttyan, 2005;
Burke et al., 2015; Capodice et al., 2009; Ekmekcioglu et al., 2011;
Huang, Chen, et al., 2011; Huang, McEntee, & Whelan, 2011;
Huang et al., 2014; Kim et al., 2012; Kunnumakkara et al., 2012;
Mohebati et al., 2012; Rafailov, Cammack, Stone, & Katz, 2007;
Sandur et al., 2007; Yan, Xie, Capodice, & Katz, 2012; Yang et al.,
2007, 2008), with prostate being the predominant focus. It has
been reported that a number of its constituents act synergis-
tically such that physiological doses are possible (Zhao, Collier,
Huang, & Whelan, 2014) and multiple mechanisms of action
have been linked in a variety of cancer cell lines by down regu-
lating the androgen receptor (Huang, Chen, et al., 2011; Huang
et al., 2014; Yan et al., 2012), insulin-like growth factor-1R
(Huang, Chen, et al., 2011; Huang, McEntee, et al. 2011), class
I and II HDACs (Huang, Chen, et al., 2011; Huang et al., 2014),
COX-1 and COX-2 activities (Bemis et al., 2005; Ekmekcioglu
et al., 2011; Kunnumakkara et al., 2012), 12-LOX and Rb protein
phosphorylation (Yang et al., 2007), and the up regulation of
tumour suppressor genes such as p21 and p27 (Bemis et al.,
2005; Huang et al., 2014). Zyflamend has also been shown to
modulate NF-κB activation (Burke et al., 2015; Kunnumakkara
et al., 2012; Sandur et al., 2007), iNOS (Ekmekcioglu et al., 2011),
apoptotic pathways (Ekmekcioglu et al., 2011; Kim et al., 2012;
Kunnumakkara et al., 2012), and aryl hydrocarbon receptor ex-
pression (Mohebati et al., 2012). It is believed that it is the
combination of bioactives that accounts for modulation of mul-
tiple pathways at relatively low doses (as described in Huang,
Chen, et al., 2011; Zhao et al., 2014).
AMP-activated protein kinase (AMPK) is a master energy
sensor in cells and responds to changes in the ratio of AMP : ATP
such that when this ratio increases it responds by increasing
ATP-generating pathways (i.e., β-oxidation) and concomi-
tantly decreasing anabolic pathways such as lipogenesis and
protein synthesis (Hardie, Ross, & Hawley, 2012b). AMPK is a
multimeric protein consisting of a catalytic subunit (α) and two
regulatory subunits (β and γ) (Hardie, Ross, & Hawley, 2012a;
Hardie et al., 2012b). Activation of AMPK involves the phos-
phorylation of Thr172 of the α-subunit. Up regulation of AMPK
activity inhibits acetyl CoA carboxylase (ACC) activity and down
regulates the expression of fatty acid synthase (FASN) and the
transcription factor sterol regulatory element binding protein-
1c (SREBP-1c), key regulators of lipogenesis. AMPK also targets
mTORC1, a complex of proteins composed of mammalian target
of rapamycin (mTOR), regulatory associated protein of mTOR
(raptor), GβL (also known as mLST8) and PRAS40 (Shaw, 2009).
This complex promotes protein synthesis and is negatively regu-
lated byAMPK, in part, via the phosphorylation of raptor. Raptor
acts as a scaffolding protein for downstream targets of the
mTOR complex such as ribosomal S6 kinase (S6K) (Shaw, 2009).
Recently, AMPK has been shown to be a potentially impor-
tant target in the treatment of prostate cancer (Flavin, Zadra,
& Loda, 2011; Wright & Stanford, 2009; Xiang, Saha, Wen,
Ruderman, & Luo, 2004; Zadra et al., 2014; Zakikhani, Dowling,
Sonenberg, & Pollak, 2008).
Recent research using Zyflamend in androgen-dependent
and castration-resistant prostate cancer cell lines suggests mul-
tiple pathways may be involved in its synergistic mechanism
of action (Huang, Chen, et al., 2011; Huang et al., 2014; Zhao
et al., 2014). Preliminary evidence from our laboratory that dem-
onstrates Zyflamend down regulates SREBP-1c and FASN
transcription and increases fatty acid oxidation suggests it may
be regulating AMPK, a new discovery related to this blend of
bioactives. Therefore, the objective of this study was to deter-
mine if Zyflamend could modulate AMPK activation and its
downstream targets, biomarkers of fatty acid synthesis and
mTORC1 signalling.These novel results, along with those pub-
lished previously, can provide a more complete picture as to
how blends of natural products may promote health and help
to reduce the risk of disease as a result of multiple mecha-
nisms of action.
2. Materials and methods
2.1. Zyflamend
Zyflamend® (New Chapter, Brattleboro,VT, USA) is derived from
the extracts of ten different commonly consumed herbs (w/
w): holy basil (Ocimum sanctum 12.8%), turmeric (Curcuma longa
14.1%), ginger (Zingiber officinale 12.8%), green tea (Camellia sinensis
12.8%), rosemary (Rosmarinus officinalis 19.2%), hu zhang (Poly-
gonum cuspidatum 10.2%), barberry (Berberis vulgaris 5.1%),
oregano (Origanum vulgare 5.1%), baikal skullcap (Scutellaria
baicalensis 2.5%), and Chinese goldthread (Coptis chinensis 5.1%).
Detailed description and characterization of the preparation
of Zyflamend and quality assurance of the mixture have been
described previously in detail (Huang, Chen, et al., 2011).
2.2. Cell culture
Human prostate cancer cell lines, CWR22Rv1 and PC3 cells
(American Type Culture Collection, Rockville, MD, USA), were
initially grown in RPMI 1640media supplemented with 10% fetal
bovine serum (FBS) under an atmosphere of 5% CO2 at 37 °C.
For the experimental treatment, CWR22Rv1 and PC3 cells were
then cultured in RPMI 1640 supplemented with 0.5% FBS con-
taining 200 µg/mL Zyflamend reconstituted in dimethyl
sulfoxide (DMSO) for cell proliferation assay, mRNA extrac-
tion, protein isolation and acetyl-CoA measurements. FBS at
a concentration of 0.5% represents an androgen depleted en-
vironment. Dose–response curves and time course experiments
were performed previously (Huang et al., 2014). HEK293 cells
(American Type Culture Collection, Rockville, MD, USA) were
grown in DMEM media supplemented with 10% FBS under an
atmosphere of 5% CO2 at 37 °C.
2.3. Cell proliferation
Cell growth and proliferation inhibition studies were per-
formed using standard 96 well plates and analysed with the
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] (Calbiochem, Darmstadt, Germany) assay following
the manufacturer’s instructions. CWR22Rv1 cells were plated
at a density of 2 × 104 cells per well. After 24 h, the FBS con-
centration in the cell culture media was reduced to 0.5% FBS
and the cells were incubated overnight prior to the addition
of the Zyflamend® (200 µg/mL), AICAR (100 µM), Compound C
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(5 µM) or recombined adenovirus. After 48 h incubation, cell vi-
ability and proliferation were measured via the MTT assay.
Briefly, the medium was replaced by 100 µL of 0.5 mg/mL MTT
in RPMI1640 media supplemented with 10% FBS and cells were
incubated for 4 h at 37 °C. Intracellular formed crystals were
solubilized with 100 µL isopropanol/0.04 N HCl.Absorbance was
read at 540 nm on a SpectraCount microplate photometer
(PerkinElmer Inc, Waltham, MA, USA).
2.4. Down regulation of AMPKα1/2 by small
interfering RNA
CWR22Rv1 cells (2 × 105 cells per well in 6-well plates, in trans-
fection medium (sc-36868, Santa Cruz Biotechnology, Dallas,
TX) were transfected with 80 pmol of siRNA targeting AMPKα1/2
(sc-29673, Santa Cruz Biotechnology, Dallas, TX, USA) and a
scrambled control siRNA (Control siRNA-A, sc-37007, Santa Cruz
Biotechnology, Dallas,TX, USA) using transfection reagent (sc-
29528, Santa Cruz Biotechnology, Dallas,TX, USA) as described
by the manufacturer. Six hours post transfection cells were cul-
tured with RPMI 1640media containing 10% FBS overnight.After
recovery, media were replaced with 0.5% FBS media contain-
ing vehicle or Zyflamend (200 µg/mL) for 30 min at 37 °C. The
total protein was harvested for Western blot.
2.5. Western blotting
Cells were lysed in RIPA cell lysis buffer (Cell Signaling Tech-
nology, Danver, MA, USA). Protein quantification was performed
using BCA protein assay kit (Pierce Biotechnology, Rockford, IL,
USA). Equal amounts of protein (20 µg) were fractioned by 8%
SDS-PAGE and transferred to a polyvinylidine difluoride (PVDF)
membrane by electroblotting. Membranes were blocked by 5%
bovine serum albumin (BSA) (Santa Cruz Biotechnology, Dallas,
TX, USA) in 0.1% Tris-buffered saline–Tween-20 (TBST) for 1 h
at room temperature and incubated inTBST containing primary
antibodies overnight at 4 °C. Membranes were incubated with
anti-mouse or anti-rabbit secondary antibody conjugated with
horseradish peroxidase (HRP) (Cell SignalingTechnology, Danver,
MA, USA). Protein expression was detected with Pierce ECL
Western Blotting detection system and membranes were
exposed to Hyperfilm Film (GE Healthcare, Piscataway, NJ, USA).
Antibodies against p-AMPKα (p172), AMPKα, p-ACC, ACC,
p-Raptor, Raptor, GβL, p-S6K, S6K, and FASN (Cell SignalingTech-
nology, Danver, MA, USA) were used to detect the target protein
level. β-actin (Santa Cruz Biotechnology, Dallas, TX, USA) was
used as the control. Band intensities were quantified by Gel-
Pro® Analyzer 4.0 (Media Cybernetics, Rockville, MD, USA).
2.6. Acetyl-coenzyme A assay
Acetyl CoA was assayed using an acetyl-coenzyme A assay kit
(Sigma-Aldrich, St. Louis, MO, USA) according to the manu-
facturer’s instructions. CWR22Rv1 cells were trypsinized and
counted prior to collection. Cells were homogenized in 400 µL
acetyl CoA assay buffer and samples were deproteinized by
adding 800 µL ice-cold 8% PCA.The resulting supernatant was
neutralized by adding 3M KHCO3. Standards were quantified
on a 0.2–1 nmol scale and 50 µL of sample was added to each
well. The plate was read on a GloMax® Microplate Reader
(Promega, Madison, WI, USA) and results were normalized to
cell number.
2.7. Construction of recombinant adenovirus
Plasmids containing cDNA of constitutively activated AMPKα1
or AMPKα2 subunits were provided by Dr. Jian Yang (Univer-
sity of Alabama,Tuscaloosa,AL, USA).AMPK cDNAwas inserted
to pACCMV plasmid and cotransfected with pJM17 into HEK293
cells by Lipofectamine 2000™ transfection reagent (Invitrogen,
Carlsbad, CA) following the manufacturer’s instruction. Re-
combinant virus termed ad-CMV-ampkα1/α2 were produced
and purified.Virus containing the bacterial β-galactosidase gene
(ad-CMV-βGal) was provided by Dr. Guoxun Chen (University
of Tennessee, Knoxville, TN, USA) and used as control.
Overexpression was verified by western blot.
2.8. RNA isolation and quantitative real time-PCR
Total RNA was isolated from CWR22Rv1 cells using Trizol®
reagent (Invitrogen, Carlsbad, CA, USA) following the manu-
facturer’s instructions. Contaminating DNA was removed from
RNA samples using a Turbo DNA freeTM kit (Ambion, Austin,
TX, USA). Concentration of total RNA was measured using a
NanoDrop 1000TM (Thermo Scientific, Wilmington, DE, USA).
Complementary DNA (cDNA) was reverse-transcripted from
RNA samples using TaqMan® reagent kit (Applied Biosystems,
Carlsbad, CA, USA) following the manufacturer’s instruc-
tions. Briefly, RNA (2 µg) was mixed with MultiScribeTM Reverse
Transcriptase, RNase Inhibitor, dNTPMixture, randomhexamers,
RT buffer, and MgCl2 solution and incubated for 10 min at 25 °C,
30 min at 48 °C, 5 min at 95 °C and then stored at 4 °C. cDNA
samples were used for quantitative RT-PCR using an ABI
Prism® 7300 Real-Time PCR System (Applied Biosystems, Carls-
bad, CA, USA). cDNA (0.7 µL) was used as a template for RT-
PCR with 2.5 µM primer sets. PCR reactions were performed
with a standard thermocycle programme: 1 min at 94 °C, fol-
lowed by 30 cycles of (15 s at 94 °C; 30 s at 50 °C; 2 min at
72 °C) followed by 5 min at 72 °C. Each sample was run in trip-
licate and normalized with 36B4. Primers for RT-PCR are listed
below:
SREBP1c, F: 5′-GCCATGGATTGCACTTT-3′, R: 5′-CAAGAG
AGGAGCTCAATG-3′ FASN, F: 5′-CGCTCGGCATGGCTATCT-3′, R:
5′-CTCGTTGAAGAACGCATCCA-3′ 36B4, F: 5′-TGCATCAGT
ACCCCATTCTATCA-3′, R: 5′-AAGGTGTAATCCGTCTCCACAGA-
3′. The relative amounts of all mRNAs were calculated using
the comparative CT method as previously described with 36B4
as the invariant control (Huang et al., 2014).
2.9. Extracellular flux analysis
The rate of change of dissolved oxygen surrounding the mono-
layer of CWR22Rv1 cells wasmeasured by an XF24 FluxAnalyzer
(Seahorse Bioscience, North Billerica, MA, USA) following the
manufacturer’s protocol. Briefly, all assays were conducted using
a seeding density of 60,000 cells/well in 500 µL of RPMI 1640
(10% FBS) in a ploy-D-lysine-coated XF24-well microplate
(Seahorse Bioscience, Billerica, MA). After culturing cells in a
CO2 incubator for 24 h, the cell medium was changed to Krebs–
Henseleit Buffer (KHB, 111mMNaCl, 4.7 mMKCl, 1.25 mMCaCl2,
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2 mM MgSO4, 1.2 mM NaH2PO4, pH 7.2) supplemented with
2.5 mM glucose, 0.5 mM carnitine and 25 mM HEPES and in-
cubated at 37 °C in a non-CO2 incubator for 1 h. Then assays
were placed in the analyser and the oxygen consumption rate
(OCR) could be detected by the fluorescent probes that contain
oxygen sensors. In this study, percent change in oxygen con-
sumption rate (%OCR) was determined in CWR22Rv1 cells
treated with vehicle (olive oil or DMSO), Zyflamend (200 µg/
mL) or AICAR (100 µM) for 1 h. Then, BSA or palmitate was
injected and the %OCR was measured over 6 cycles. At the end
of the 6 cycles, etomoxir (50 µM), a fatty acid oxidation inhibi-
tor, was injected and %OCR was measured over 3 additional
cycles. The total contribution of palmitate oxidation towards
OCR (%) was observed after injection of etomoxir. The rela-
tive palmitate oxidation was determined by determining the
difference before and after etomoxir injection in vehicle groups
compared to Zyflamend or AICAR treatment groups.
2.10. Statistical analysis
The results are presented as mean ± SD.The data from the ex-
tracellular flux analysis are presented as mean ± SEM. For two
group comparisons, the data were analysed by two-tailed Stu-
dent’s T-test. For multiple comparisons, the results were
analysed by an ANOVA followed by Tukey’s post hoc analysis
when appropriate. Differences were considered significant at
p < 0.05.
Fig. 1 – The effects of Zyflamend on SREBP-1c and FASN expression and phosphorylation of AMPKα. (A) mRNA levels of
SREBP1c and FASN from CWR22Rv1 cells treated in the presence or absence of Zyflamend (200 µg/mL). (B) Western blot for
FASN from CWR22Rv1 cells treated with Zyflamend (200 µg/mL). (C, D) The effects of Zyflamend on phosphorylation of
AMPKα in CWR22Rv1 and PC3 prostate cancer cell lines. (C) Protein levels of p-AMPKα were determined in CWR22Rv1 cells
treated ± Zyflamend (200 µg/mL, 0–3 h) with data (relative ratios of p-AMPK/t-AMPK) summarized at the 30 min time point
(bar graph). (D) Protein levels of p-AMPKα (relative ratios of p-AMPK/t-AMPK) were determined in PC3 cells
treated ± Zyflamend (200 µg/mL, 30 min). Data are presented as mean ± SD, n = 3. Group comparisons, Zyflamend versus
control, * p < 0.05.
150 J o u rna l o f Func t i ona l F ood s 1 8 ( 2 0 1 5 ) 1 4 7 – 1 5 8
3. Results
3.1. Zyflamend inhibited de novo fatty acid synthesis in
CWR22Rv1 cells
In preliminary experiments using CWR22Rv1 cells, Zyflamend
treatment (24 h) significantly decreased mRNA levels of FASN
and SREBP-1c, the major transcriptional regulator of enzymes
in lipogenic pathways (including FASN), by ~60% (Fig. 1A). The
effect of Zyflamend on the protein level of FASN (24 h) is pre-
sented in Fig. 1B.
3.2. Zyflamend regulates AMPK phosphorylation in
CWR22Rv1 and PC3 prostate cancer cell lines
In CWR22Rv1 cells, phosphorylation of AMPKα (T172) was in-
creased by Zyflamend (200 µg/mL) ~ 3.5 fold after 30 min
treatment (Fig. 1C). Similarly, Zyflamend increased the phos-
phorylation of AMPKα (T172) by ~2 fold in PC3 cells (Fig. 1D).
3.3. Zyflamend regulates downstream targets of AMPK
ACC and mTORC1 complex are two major downstream targets
of AMPK. In CWR22Rv1 cells, Zyflamend (200 µg/mL)
increased phosphorylation of ACC ~2 fold after 30 min treat-
ment (Fig. 2A, B). The cellular levels of acetyl CoA significantly
increased by about 1.5 fold after 24 h treatment of Zyflamend
(Fig. 2C).
Regarding mTORC1 complex which includes raptor and GβL
(Kim et al., 2003), Zyflamend treatment increased phosphory-
lation of raptor ~4 fold after 30 min treatment (Fig. 2A, B).
Phosphorylation of S6K, a downstream biomarker for activity
of mTORC1 complex, was reduced in a time dependent manner
(0.5–3 h) with Zyflamend treatment (Fig. 2A, B). In the pres-
ence of Zyflamend, GβL protein levels decreased in a time
dependent manner (Fig. 2A, B). Increases in the phosphoryla-
tion of ACC and raptor were replicated in CWR22Rv1 cells
following treatment with the positive control, AICAR (Fig. 3A,
B), and in PC3 cells following treatment with Zyflamend (Fig. 3C,
D).
To confirm that Zyflamend increased phosphorylation of ACC
and raptor by increasing the activity of AMPK,we knocked down
AMPKα1/2 subunit by siRNA. Transient knockdown by siRNA
transfection resulted in a 50% reduction of AMPKα protein levels
(Fig. 4A, B). Concomitantly, phosphorylation of ACC and raptor
was decreased by about 50% after AMPKα knockdown.The ad-
dition of Zyflamend attenuated the effects of siRNA knockdown
of AMPKα1/2 on phosphorylation of ACC and raptor (Fig. 4A,
C, D), but did not attain those of Zyflamend-treated controls.
Fig. 2 – Regulation of downstream targets of AMPK by ±Zyflamend in CWR22Rv1 cells. (A, B) The effects of Zyflamend
treatment (0.5–3 h) on phosphorylation of ACC, raptor and S6K (relative to total ACC, total raptor and total S6K, respectively)
and protein levels of GβL. Data are presented as mean ± SD, n = 3. Group comparisons, Zyflamend versus control, * p < 0.05.
(C) Effects of Zyflamend on total cellular levels of acetyl CoA. Data are presented as mean ± SD, n = 3. Group comparisons,
Zyflamend versus control, * p < 0.05.
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3.4. Zyflamend increased fatty acid oxidation in
CWR22Rv1 cells
As a consequence of activation of AMPK and inactivation of
ACC, we next sought to determine if Zyflamend increases fatty
acid oxidation. Towards this end, we used an XF24 Flux Ana-
lyzer (Seahorse Biosciences) to assess palmitate oxidation in
CWR22Rv1 cells treated with Zyflamend or vehicle control.The
change in the oxygen consumption rate (OCR) from baseline
increased in CWR22Rv1 cells treated with Zyflamend com-
pared to the olive oil vehicle control (Fig. 5A). This effect was
negated after injection of etomoxir, an inhibitor of fatty acid
oxidation.The difference in OCR before and after etomoxir in-
jection was used to calculate the relative palmitate oxidation,
which was approximately 4-fold higher in the Zyflamend group
as compared to control (Fig. 5B). As a comparison, the AMPK
activator AICAR also stimulated palmitate oxidation to a similar
extent as that of Zyflamend (Fig. 5C, D).
3.5. Zyflamend decreased CWR22Rv1 cell viability, in
part, through the activation of AMPK
Inhibiting AMPK activity by compound C modestly enhanced
CWR22Rv1 cell viability after 48 h treatment (Fig. 6A). Zyflamend
decreased cell viability and this effect was partially attenu-
ated with the concomitant treatment of compound C (Fig. 6A).
To mimic the effect of Zyflamend’s induction of phosphory-
lation of AMPKα, cells were treated with AICAR, a knownAMPK
activator. AICAR (100 µM) treatment decreased cell viability by
about 20% after 48 h treatment (Fig. 6C).Treatment with AICAR
plus Zyflamend resulted in an additional decrease in cell
viability (~30%) (Fig. 6C). Overexpression of AMPKα1/2 sub-
units (as confirmed by western blot, Fig. 6B) inhibited cell
viability in CWR22Rv1 cells by 40% (Fig. 6C), and this effect was
augmented in the presence of Zyflamend.
4. Discussion
Zyflamend is a commercial product composed of the ex-
tracts of ten herbs. Its original formulation almost 2 decades
ago was based on those herbs that had antioxidant and anti-
inflammatory properties. Its subsequent use in experimental
investigations in an assortment of cancer models has drawn
attention by a variety of laboratories interested in the role of
natural products in health and disease (Bemis et al., 2005; Burke
et al., 2015; Capodice et al., 2009; Ekmekcioglu et al., 2011;
Huang, Chen, et al., 2011; Huang, McEntee, et al. 2011; Huang
et al., 2014; Kim et al., 2012; Kunnumakkara et al., 2012;
Mohebati et al., 2012; Rafailov et al., 2007; Sandur et al., 2007;
Yan et al., 2012; Yang et al., 2007, 2008).
There are always concerns regarding reproducibility and
quality control of commercial products. The quality control in
the preparation of these extracts has been described in detail
elsewhere (Huang, Chen, et al., 2011). Assurance of that quality
control has been verified by the corroborative reproducible
results generated at different times, with different lots, in mul-
tiple laboratories, under different circumstances, using similar
and different cell lines with similar concentrations (Bemis et al.,
2005; Burke et al., 2015; Capodice et al., 2009; Ekmekcioglu et al.,
2011; Huang, Chen, et al., 2011; Huang, McEntee, et al. 2011;
Fig. 3 – Regulation of downstream targets of AMPK by AICAR in CWR22Rv1 cells and Zyflamend (Zyf) in PC3 cells. (A, B) The
effects of AICAR (positive control) on phosphorylation of ACC and raptor in CWR22Rv1 cells (black bar: without AICAR; grey
bar: with AICAR). (C, D) The effects of Zyflamend on phosphorylation of ACC and raptor in PC3 cells (black bar: without
Zyflamend; grey bar: with Zyflamend). Data are presented as mean ± SD, n = 3. Group comparisons, AICAR or Zyflamend
versus control,* p < 0.05.
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Huang et al., 2014; Kim et al., 2012; Kunnumakkara et al., 2012;
Mohebati et al., 2012; Rafailov et al., 2007; Sandur et al., 2007;
Yan et al., 2012; Yang et al., 2007, 2008). The best combina-
tions of extracts within this formulation have not been
systematically determined because it would be infeasible to
reproduce the results from 1028 possible combinations.
However, recent evidence using biologic and molecular end-
points suggests that the compendium of compounds found in
individual extracts is synergistically more efficacious than iso-
lated bioactives derived from those extracts and that the
combinations of extracts are synergistically more efficacious
than the extracts used individually (Zhao et al., 2014). These
combinations are more likely to have bioactivity at concen-
trations that would bemore physiologically relevant (Zhao et al.,
2014). Furthermore, the use of well-defined extracts in testing
mechanisms of action provides evidence more related to how
people eat (viz. people eat foods with their complexity of
bioactives, not purified compounds from those foods). As such,
generating mechanisms of action using well-defined combi-
nations should further the understanding of the food–health
relationship.
In our laboratory, we have been studying the effects of
Zyflamend on preclinical models of chronic diseases, includ-
ing cancer (Huang, Chen, et al., 2011; Huang, McEntee, et al.
2011; Huang et al., 2014) and diabetes (Burke et al., 2015), with
an emphasis on castration-resistant prostate cancer (Huang,
Chen, et al., 2011; Huang, McEntee, et al. 2011; Huang et al.,
2014) using cell lines derived from the CWR22 lineage
(Nagabhushan et al., 1996; Pretlow et al., 1993). We focus our
attention on this lineage because the androgen dependent
CWR22 cells can relapse into the androgen-insensitive CWR22R
cell line in vivo following androgen deprivation (McEntee et al.,
2008; Nagabhushan et al., 1996). These cells, unlike the andro-
gen independent PC3 cell line, have a functional androgen
receptor and produce prostate specific antigen, common char-
acteristics in human castration-resistant prostate cancer.
Our data pertaining to Zyflamend and several studies from
other laboratories (Bemis et al., 2005; Burke et al., 2015; Capodice
et al., 2009; Ekmekcioglu et al., 2011; Huang, Chen, et al., 2011;
Huang, McEntee, et al. 2011; Huang et al., 2014; Kim et al., 2012;
Kunnumakkara et al., 2012; Mohebati et al., 2012; Rafailov et al.,
2007; Sandur et al., 2007; Yan et al., 2012; Yang et al., 2007, 2008)
reveal diverse mechanisms of action, possibly explaining its
robust effects using in vivomodels of tumorigenesis at oral doses
that mimic human intakes (Huang, Chen, et al., 2011;
Kunnumakkara et al., 2012). Because herbal extracts are com-
posed of multiple compounds, it is difficult to directly
extrapolate a standard concentration. The concentration of
Fig. 4 – The effects of partial knockdown of AMPKα1/2 on phosphorylation of ACC and raptor in the presence or absence of
Zyflamend. (A, C, D) Western blot of p-ACC and p-raptor following knockdown of AMPKα1/2 in the presence or absence of
Zyflamend. Data are presented as mean ± SD, n = 3. a,b,c,dBars with different letters within each figure are significantly
different at p < 0.05; (B) Group comparison, siAMPKα versus control,* p < 0.05.
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Zyflamend used in this study was based on the physiological
achievable concentration of curcumin.The maximum dose of
Zyflamend (200 µg/mL) was chosen based on the levels of
curcumoids found in the polymixture (~7% w/w in turmeric)
(Braga, Leal, Carvalho, & Meireles, 2003) and this was matched
to the highest identifiable levels reported in human plasma con-
centrations (~2 µM) following an oral supplementation of 8 g/d
over a 3 month period (Cheng et al., 2001). It has been sug-
gested that these levels in vitro could have human physiological
relevance (Howells et al., 2007); however, the results gener-
ated in this study need to be investigated in vivo for
confirmation.
The objective of this study was to follow up on previous
studies and demonstrate that Zyflamend inhibits lipogenesis
by down regulating SREBP-1c and FASN expression and en-
hancing fatty acid oxidation.To support the rapid proliferation
of cancer cells, up regulation of de novo fatty acid synthesis is
commonly found in solid tumours, including prostate, and this
metabolic shift supporting anabolic processes can be the result
of dysregulation of AMPK (Flavin et al., 2011; Zadra et al., 2014).
Therefore, we logically investigated the effect of Zyflamend on
AMPK activation as determined by modulation of its well-
accepted downstream targets involved in lipogenesis and
mTORC1 signalling. Regulation of AMPK has become an im-
portant target for cancer treatment. AMPK activators, such as
MT63-78, metformin and AICAR, have been shown to be in-
hibitors of prostate cancer in a variety of preclinical models
(Xiang et al., 2004; Zadra et al., 2014).
Zyflamend increased AMPK activity by increasing phos-
phorylation of Thr172 of the catalytic subunit, resulting in
inhibition of fatty acid synthesis, in part, via the phosphory-
lation of ACC. Importantly, de novo phospholipid biosynthesis
Fig. 5 – The effect of Zyflamend and AICAR on palmitate oxidation in CWR22Rv1 cells. Percent change in oxygen
consumption rate (%OCR) in CWR22Rv1 cells treated with vehicle (olive oil or DMSO), Zyflamend or AICAR for 1 h. Then, BSA
or palmitate was injected and the %OCR was measured over 6 cycles. At the end of the 6 cycles, etomoxir (50 µM), a fatty
acid oxidation inhibitor, was injected and %OCR was measured over 3 additional cycles. The total contribution of palmitate
oxidation towards %OCR is observed after injection of etomoxir (A, C). The relative palmitate oxidation was determined by
determining the difference before and after etomoxir injection in vehicle groups compared to Zyflamend or AICAR
treatment groups. Data points for panels B and D represent the average OCR (%) over 3–5 replicates per experimental
condition. Error bars represent ±SEM. [Abbreviations: AU, arbitrary units; ETO, etomoxir (carnitine palmitoyl transferase-1
inhibitor)]. AU – area under the curve after injection of palmitate for each treatment and normalized to etomoxir treatment.
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has been shown to be a primary target for fatty acids from this
pathway (Zadra et al., 2014). These results are consistent with
previous studies investigating AMPK activation using a variety
of prostate cancer cell lines, where multiple AMPK activators
increased phosphorylation of AMPK, ACC, raptor, and inhib-
ited phosphorylation of S6K (Zadra et al., 2014). Furthermore,
our results demonstrating that Zyflamend increased fatty acid
oxidation are consistent with AMPK activation as deter-
mined by radioactive CO2 production using in vivo and in vitro
models of prostate cancer (Zadra et al., 2014). Collectively, these
results suggest that treatment of CWR22Rv1 cells with
Zyflamend results in activation of AMPK that leads to a meta-
bolic adaptation by which the cells shift from an anabolic state
towards a more catabolic state, thereby diminishing fatty acid
synthesis and other anabolic processes required to drive
proliferation.
Replication of AMPK activation was demonstrated via the
inhibition of mTORC1 signalling, and our results are similar
to those of others who used a variety of tools to activate AMPK
(Xiang et al., 2004; Zadra et al., 2014). Knockdown and over-
expression experiments and the use of AICAR and compound
C confirmed Zyflamend’s role in regulating AMPK activation
and its downstream signalling.
Four kinases have been identified that phosphorylate AMPKα
at Thr172, liver kinase B1 (LKB1) (Hawley et al., 1996), calcium/
calmodulin-dependent protein kinase kinase β (CaMKKβ)
(Hawley et al., 2005), transforming growth factor-β activated
protein kinase-1 (TAK1) (Herrero-Martin et al., 2009; Momcilovic,
Hong, & Carlson, 2006), andmost recently mixed-lineage kinase
3 (MLK3) (Luo, Jiang, Huang, Lu, & Luo, 2015). LKB1 is consid-
ered a tumour suppressor because mutation/inactivation of its
gene is associated with a variety of cancers (Gan & Li, 2014).
Expression of LKB1 has been reported to be lower in human
prostate cancer tissue as compared to normal tissue (Xu, Cai,
Liu, & Guo, 2014). Similar results were observed in PC3 and
DU145 prostate cancer cell lines compared to control cells
Fig. 6 – The effects on modulating AMPK activity on cell viability with the AMPK inhibitor compound C and overexpression
of AMPKα1/2 subunits in the presence or absence of Zyflamend in CWR22Rv1 cells. (A) The effects of cell viability following
treatment with compound C, in the presence or absence of Zyflamend. Data are presented as mean ± SD, n = 8. a,b,c,dBars
with different letters are significantly different at p < 0.05. (B) Overexpression by adenovirus as confirmed by western blot.
(C) The effects of overexpression of AMPKα1/2 subunits on cell viability in the presence (black bar) or absence (grey bar) of
Zyflamend. Data are presented as mean ± SD, n = 8. Bars with different letters (a,b,c,d or A’,B’,C’) are significantly different at
p < 0.05 (a,b,c,d represent statistical comparisons of the black bars, and A’,B’,C’ represent statistical comparisons of the grey
bars).Within group comparisons ±Zyflamend, * p < 0.05.
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(RWPE-1), and knockdown of LKB1 promoted their prolifera-
tion (Xu et al., 2014). Unlike LKB1, the activity of CaMKKβ is
not sensitive to ATP : AMP ratios, but rather to increases in in-
tracellular Ca2+ levels. CaMKKβ has been negatively associated
with castration-resistant prostate cancer where loss of CaMKKβ
increases proliferation and overexpression reduces tumour
growth in vivo (Shima et al., 2012). There is also some evi-
dence suggesting that deletion of MAP3K7, the gene that
encodes for TAK1 protein, is positively associated with pros-
tate cancer (Kluth et al., 2013), with a potential interaction
between LKB1 and TAK1 (Xie et al., 2006). While we have not
investigated upstream signalling of AMPK, our preliminary data
show that chemical inhibitors of LKB1 (radicicol) and CaMKKβ
(STO-609) reduced phosphorylation of AMPK (data not shown).
Treatment with Zyflamend only in the presence of the CaMKKβ
inhibitor restored pAMPK to untreated control levels.These data
suggest that Zyflamend-stimulated phosphorylation of AMPK
is independent of CaMKKβ activity and may be related in part
to LKB1. The role of Zyflamend on the upstream regulation of
AMPK will be further explored in future studies.
Recent data have strongly suggested that AMPK activation
may also be linked to inhibition of PSA and androgen recep-
tor expression, along with increases in p21 (Zadra et al., 2014),
characteristics shared by Zyflamend treatment (Huang, Chen,
et al., 2011; Huang, McEntee, et al. 2011; Huang et al., 2014).
Castration-resistant forms of the disease coordinately involve
activation of the androgen receptor in the absence of andro-
gens coupled with higher expression of lipogenic genes
compared with prostate cancer cells that are androgen-
dependent (Ettinger et al., 2004; Swinnen, Ulrix, Heyns, &
Verhoeven, 1997; Zadra et al., 2014).
5. Conclusion
In summary, Zyflamend is a polyherbal mixture whose com-
ponents have been shown to act synergistically against cancer
in a variety of models. It has been clearly established that ac-
tivation of AMPK can inhibit mTORC1 signalling, the expressions
of androgen receptor, p21, SREBP-1c and FASN, inhibit ACC ac-
tivity, and increase fatty acid oxidation. Zyflamend also
replicates these same effects. Based on these results and those
previously published in other cancer models, investigations in-
volving the effects of combinations of natural products, such
as those found in Zyflamend, should be encouraged.
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